Bruce L. A. Carter - 21 Mar 2022 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Director
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
21 Mar 2022
Net transactions value
-$253,490
Form type
4
Filing time
22 Mar 2022, 17:52:56 UTC
Previous filing
07 Mar 2022
Next filing
16 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $153,480 +6,000 $25.58 6,000 21 Mar 2022 Direct
transaction ENTA Common Stock Sale $178,489 -2,676 -45% $66.70 3,324 21 Mar 2022 Direct F1, F2
transaction ENTA Common Stock Sale $20,640 -307 -9.2% $67.23 3,017 21 Mar 2022 Direct F1, F3
transaction ENTA Common Stock Sale $151,739 -2,210 -73% $68.66 807 21 Mar 2022 Direct F1, F4
transaction ENTA Common Stock Sale $56,103 -807 -100% $69.52 0 21 Mar 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -6,000 -100% $0.000000* 0 21 Mar 2022 Common Stock 6,000 $25.58 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $66.28 to $66.99, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $67.005 to $67.47, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $68.509 to $68.76, inclusive.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $69.39 to $70.07, inclusive.
F6 100% of the shares subject to the option are fully vested and exercisable.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5 above.